This library documents peer-reviewed clinical evidence supporting Anti-na® SIPS — a dissolvable dietary supplement combining 2,000mg therapeutic ginger root extract and 1,000mg Bioenergy Ribose® (D-Ribose) for chemotherapy-induced nausea and vomiting (CINV, ICD-10: R11) and cancer-related fatigue (ICD-10: R53.0). All citations include direct PubMed links.
Peer-reviewed research on therapeutic ginger for CINV and D-Ribose for cellular energy support — with direct PubMed links for every citation.
About this library: The studies below represent key research supporting the formulation of Anti-na® SIPS. This is not an exhaustive meta-analysis. PubMed links open in a new tab. If a study is behind a paywall, the abstract is freely available at the PubMed link. Contact orders@kddnutra.com with questions about specific citations.
Landmark phase II/III RCT involving 576 cancer patients receiving platinum-based chemotherapy. Patients were randomized to placebo, 0.5g, 1.0g, or 1.5g ginger daily. The 0.5g and 1.0g doses (equivalent to 500–1,000mg ginger) significantly reduced acute nausea on day 1 of chemotherapy versus placebo. All doses were well-tolerated. This is one of the most-cited trials on ginger for CINV.
Randomized double-blind placebo-controlled pilot study in 162 cancer patients. Ginger supplementation at 1,000mg or 2,000mg daily significantly reduced nausea severity, particularly acute nausea. The 2,000mg dose showed comparable efficacy to the 1,000mg dose with continued favorable tolerability.
Comprehensive mechanism review establishing that gingerols and shogaols act as 5-HT3 receptor antagonists — the same receptor pathway targeted by prescription antiemetics such as ondansetron. Also identifies NK1 receptor modulation and gastric motility enhancement as key mechanisms.
Multicenter RCT of 251 patients across 8 Italian oncology centers. Ginger extract (160mg ginger dry extract standardized to 20% gingerols — equivalent to ~800–1000mg whole ginger) significantly reduced delayed nausea incidence compared to placebo. No significant adverse effects.
Pediatric oncology study examining ginger as an adjunct to ondansetron for cisplatin-induced nausea. The ginger + ondansetron combination was significantly more effective than ondansetron alone in reducing both acute and delayed nausea episodes.
NCCN guidelines acknowledge ginger as a complementary intervention with evidence supporting its use alongside standard antiemetic protocols for CINV management. Categorized as having "low-level evidence" for acute nausea and "moderate evidence" as an adjunct therapy.
Systematic review of 12 randomized controlled trials encompassing both pregnancy nausea and CINV. Concludes that ginger is a safe and effective non-pharmacological option for reducing nausea across multiple clinical contexts. Identifies the optimal dose range as 1,000–2,000mg/day.
Meta-analysis of 11 RCTs (1,217 patients). Concluded that ginger supplementation significantly reduces the severity of acute chemotherapy-induced nausea compared to placebo or standard care alone. Effect sizes were larger at doses ≥1,000mg/day.
Open-label multicenter pilot study examining D-Ribose supplementation (5g three times daily) in patients with chronic fatigue syndrome and fibromyalgia — conditions characterized by mitochondrial energy depletion. Significant improvements in energy, sleep, mental clarity, pain, and overall wellbeing. Average energy improvement of 45% on a visual analog scale.
Landmark randomized double-blind crossover study in The Lancet demonstrating that D-Ribose supplementation significantly improved exercise tolerance and time to ischemia in patients with coronary artery disease. Established the mechanism: D-Ribose accelerates ATP resynthesis in metabolically stressed tissue.
Examined D-Ribose supplementation following high-intensity exercise in trained subjects. Demonstrated that D-Ribose accelerates adenine nucleotide (AMP, ADP, ATP) resynthesis in skeletal muscle during recovery — with recovery rates significantly faster than in the placebo group.
Demonstrated that D-Ribose supplementation results in significantly faster ATP resynthesis rates following exercise-induced depletion compared to glucose alone. ATP resynthesis with D-Ribose was approximately 3.4x faster than with glucose in depleted muscle tissue.
Observational study in 257 heart failure patients supplemented with D-Ribose over an average of 3 weeks. Significant improvements in quality of life, energy levels, and functional capacity. D-Ribose was associated with subjective fatigue reduction in 66% of patients.
Important notice: The studies listed above are provided for informational and educational purposes. They are independent peer-reviewed publications and do not constitute endorsement of Anti-na® SIPS by the study authors or their institutions. Anti-na® SIPS is a dietary supplement and these statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For clinical questions, contact orders@kddnutra.com.
For clinical inquiries, additional citations, or information about recommending SIPS to your patients.